{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:33:13Z","timestamp":1777091593881,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10637-013-9998-8","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T12:18:10Z","timestamp":1375273090000},"page":"303-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study"],"prefix":"10.1007","volume":"32","author":[{"given":"Patricia M.","family":"LoRusso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smitha","family":"Krishnamurthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Youssoufian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floyd","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna","family":"Dontabhaktuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitri","family":"Grebennik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot","family":"Remick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"issue":"3","key":"9998_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.V97.3.785","volume":"97","author":"A Sawano","year":"2001","unstructured":"Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M (2001) Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97(3):785\u2013791","journal-title":"Blood"},{"issue":"3","key":"9998_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1620\/tjem.185.173","volume":"185","author":"K Sato","year":"1998","unstructured":"Sato K, Sasaki R, Ogura Y, Shimoda N, Togashi H, Terada K, Sugiyama T, Kakinuma H, Ogawa O, Kato T (1998) Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J Exp Med 185(3):173\u2013184","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"9998_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X","volume":"188","author":"M Decaussin","year":"1999","unstructured":"Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E (1999) Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1\/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188(4):369\u2013377","journal-title":"J Pathol"},{"key":"9998_CR4","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1182\/blood-2004-01-0226","volume":"104","author":"ES Wang","year":"2004","unstructured":"Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA (2004) Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 104:2893\u20132902","journal-title":"Blood"},{"key":"9998_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nrc2524","volume":"8","author":"C Fischer","year":"2008","unstructured":"Fischer C, Mazzone M, Jonckx B, Carmeliet P (2008) FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8:942\u2013956","journal-title":"Nat Rev Cancer"},{"issue":"4 suppl","key":"9998_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/cncr.24789","volume":"116","author":"JD Schwartz","year":"2010","unstructured":"Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y (2010) Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer 116(4 suppl):1027\u20131032. doi:10.1002\/cncr.24789","journal-title":"Cancer"},{"issue":"8","key":"9998_CR7","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/0008-5472.CAN-04-3598","volume":"65","author":"L Vincent","year":"2005","unstructured":"Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, Pytowski B, Wu Y, Hicklin DJ, Zhu Z, Bohlen P, Niesvizky R, Rafii S (2005) Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a\/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer Res 65(8):3185\u20133192","journal-title":"Cancer Res"},{"key":"9998_CR8","doi-asserted-by":"publisher","first-page":"11089","DOI":"10.1158\/0008-5472.CAN-06-2407","volume":"66","author":"RN Kaplan","year":"2006","unstructured":"Kaplan RN, Rafii S, Lyden D (2006) Preparing the \u201csoil\u201d: the premetastatic niche. Cancer Res 66:11089\u201311093","journal-title":"Cancer Res"},{"issue":"11","key":"9998_CR9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/nm1101-1194","volume":"7","author":"D Lyden","year":"2001","unstructured":"Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7(11):1194\u20131201","journal-title":"Nat Med"},{"key":"9998_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc1256","volume":"4","author":"JW Pollard","year":"2004","unstructured":"Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71\u201378","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"9998_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1535-6108(02)00153-8","volume":"2","author":"S Hiratsuka","year":"2002","unstructured":"Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2(4):289\u2013300","journal-title":"Cancer Cell"},{"issue":"21","key":"9998_CR12","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.1158\/1078-0432.CCR-06-0831","volume":"12","author":"Y Wu","year":"2006","unstructured":"Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ (2006) Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 12(21):6573\u20136584","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9998_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1517\/14728222.2011.641951","volume":"16","author":"MJ Waldner","year":"2012","unstructured":"Waldner MJ, Neurath MF (2012) Targeting the VEGF signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):5\u201313. doi:10.1517\/14728222.2011.641951","journal-title":"Expert Opin Ther Targets"},{"issue":"18","key":"9998_CR14","first-page":"5117","volume":"60","author":"RA Brekken","year":"2000","unstructured":"Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE (2000) Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR\/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60(18):5117\u20135124","journal-title":"Cancer Res"},{"issue":"5","key":"9998_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.yexcr.2005.11.012","volume":"312","author":"M Shibuya","year":"2006","unstructured":"Shibuya M, Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312(5):549\u2013560","journal-title":"Exp Cell Res"},{"issue":"59","key":"9998_CR16","doi-asserted-by":"publisher","first-page":"re1","DOI":"10.1126\/scisignal.259re1","volume":"2","author":"Y Cao","year":"2009","unstructured":"Cao Y (2009) Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2(59):re1. doi:10.1126\/scisignal.259re1","journal-title":"Sci Signal"},{"key":"9998_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011\u20131027","journal-title":"J Clin Oncol"},{"issue":"3","key":"9998_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","volume":"62","author":"R Roskoski Jr","year":"2007","unstructured":"Roskoski R Jr (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62(3):179\u2013213","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"9998_CR19","first-page":"1952","volume":"58","author":"RA Brekken","year":"1998","unstructured":"Brekken RA, Huang X, King SW, Thorpe PE (1998) Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58(9):1952\u20131959","journal-title":"Cancer Res"},{"issue":"9","key":"9998_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrclinonc.2009.110","volume":"6","author":"A Grothey","year":"2009","unstructured":"Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6(9):507\u2013518. doi:10.1038\/nrclinonc.2009.110","journal-title":"Nat Rev Clin Oncol"},{"issue":"28","key":"9998_CR21","doi-asserted-by":"publisher","first-page":"11306","DOI":"10.1073\/pnas.1203275109","volume":"109","author":"SB Sunshine","year":"2012","unstructured":"Sunshine SB, Dallabrida SM, Durand E, Ismail NS, Bazinet L, Birsner AE, Sohn R, Ikeda S, Pu WT, Kulke MH, Javaherian K, Zurakowski D, Folkman JM, Rupnick M (2012) Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A 109(28):11306\u201311311. doi:10.1073\/pnas.1203275109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"9998_CR22","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","volume":"16","author":"R Dienstmann","year":"2011","unstructured":"Dienstmann R, Bra\u00f1a I, Rodon J, Tabernero J (2011) Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 16(12):1729\u20131740. doi:10.1634\/theoncologist.2011-0163","journal-title":"Oncologist"},{"issue":"6","key":"9998_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","volume":"30","author":"ES Robinson","year":"2010","unstructured":"Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD (2010) Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 30(6):591\u2013601. doi:10.1016\/j.semnephrol 2010.09.007","journal-title":"Semin Nephrol"},{"issue":"4","key":"9998_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2174\/157016112800812836","volume":"10","author":"P Ferroni","year":"2012","unstructured":"Ferroni P, Della-Morte D, Palmirotta R, Rundek T, Guadagni F, Roselli M (2012) Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies. Curr Vasc Pharmacol 10(4):479\u2013493","journal-title":"Curr Vasc Pharmacol"},{"issue":"3","key":"9998_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/157016111795495503","volume":"9","author":"S Thanigaimani","year":"2011","unstructured":"Thanigaimani S, Kichenadasse G, Mangoni AA (2011) The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol 9(3):358\u2013380","journal-title":"Curr Vasc Pharmacol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9998-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-9998-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9998-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9998-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:46:14Z","timestamp":1678509974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-9998-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["9998"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-9998-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,1]]},"assertion":[{"value":"30 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}